Compare Divis Laboratories with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALEMBIC - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALEMBIC DIVIS LABORATORIES/
ALEMBIC
 
P/E (TTM) x 57.6 77.6 74.2% View Chart
P/BV x 15.4 6.7 230.1% View Chart
Dividend Yield % 0.4 0.2 260.4%  

Financials

 DIVIS LABORATORIES   ALEMBIC
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ALEMBIC
Mar-18
DIVIS LABORATORIES/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs1,63972 2,276.8%   
Low Rs1,11534 3,289.1%   
Sales per share (Unadj.) Rs186.34.7 3,963.8%  
Earnings per share (Unadj.) Rs51.06.1 834.9%  
Cash flow per share (Unadj.) Rs57.36.2 917.8%  
Dividends per share (Unadj.) Rs16.000.20 8,000.0%  
Dividend yield (eoy) %1.20.4 307.6%  
Book value per share (Unadj.) Rs261.840.7 643.8%  
Shares outstanding (eoy) m265.47267.03 99.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.411.3 65.6%   
Avg P/E ratio x27.08.7 311.5%  
P/CF ratio (eoy) x24.08.5 283.4%  
Price / Book Value ratio x5.31.3 404.0%  
Dividend payout %31.43.3 958.2%   
Avg Mkt Cap Rs m365,59214,139 2,585.7%   
No. of employees `00011.8NA-   
Total wages/salary Rs m5,423207 2,614.6%   
Avg. sales/employee Rs Th4,175.1NM-  
Avg. wages/employee Rs Th457.7NM-  
Avg. net profit/employee Rs Th1,141.8NM-  
INCOME DATA
Net Sales Rs m49,4631,255 3,940.6%  
Other income Rs m1,556370 420.4%   
Total revenues Rs m51,0191,625 3,138.9%   
Gross profit Rs m18,718111 16,848.2%  
Depreciation Rs m1,68938 4,468.3%   
Interest Rs m352 2,058.8%   
Profit before tax Rs m18,551442 4,198.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,02324 20,974.1%   
Profit after tax Rs m13,5271,630 830.0%  
Gross profit margin %37.88.9 427.6%  
Effective tax rate %27.15.4 499.5%   
Net profit margin %27.3129.8 21.1%  
BALANCE SHEET DATA
Current assets Rs m46,5011,867 2,490.5%   
Current liabilities Rs m8,468591 1,432.3%   
Net working cap to sales %76.9101.6 75.6%  
Current ratio x5.53.2 173.9%  
Inventory Days Days13194 138.8%  
Debtors Days Days8674 116.7%  
Net fixed assets Rs m25,7971,791 1,440.4%   
Share capital Rs m531534 99.4%   
"Free" reserves Rs m68,96210,324 668.0%   
Net worth Rs m69,49310,858 640.0%   
Long term debt Rs m041 0.0%   
Total assets Rs m80,38311,591 693.5%  
Interest coverage x531.0260.9 203.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.1 568.2%   
Return on assets %16.914.1 119.9%  
Return on equity %19.515.0 129.7%  
Return on capital %26.715.2 176.1%  
Exports to sales %01.5 0.0%   
Imports to sales %24.621.0 117.4%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs m12,187263 4,627.8%   
Fx inflow Rs m41,23819 212,564.9%   
Fx outflow Rs m12,405264 4,702.1%   
Net fx Rs m28,833-244 -11,796.3%   
CASH FLOW
From Operations Rs m9,543236 4,047.1%  
From Investments Rs m-6,854-224 3,059.8%  
From Financial Activity Rs m-2,459-27 9,245.9%  
Net Cashflow Rs m230-15 -1,551.4%  

Share Holding

Indian Promoters % 52.0 64.0 81.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.2 5,900.0%  
FIIs % 19.0 9.7 195.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 26.1 65.9%  
Shareholders   31,796 54,701 58.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


May 7, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS